Group 1: Market Expansion Strategies - The company is focusing on international market expansion, primarily targeting Southeast Asia, Middle East and Africa, Europe, Americas, and India and Australia, leveraging its unique solution capabilities and cost-effective services to attract customers [2] - The overseas business is entering a rapid growth phase, with significant breakthroughs achieved in the Middle East and Southeast Asia, attributed to strategic planning and resource investment over the past 3-5 years [2] Group 2: Financial Performance Outlook - The company's overall gross margin for 2025 is expected to remain around 30%, with a steady increase anticipated due to ongoing cost reduction and efficiency improvement measures [2] - The company aims for stable growth in operating performance, supported by its commitment to high-quality development [2] Group 3: Product and Business Development - The domestic market for consumables has not met expectations this year due to industry conditions, while significant breakthroughs have been made in the international market for Chu Tian Si You Te [3] - The company is actively expanding its market for Chu Tian Microbead products, with customer sample points gradually established, indicating potential for future growth [3] Group 4: Goodwill and Risk Assessment - The risk of goodwill impairment for ROMACO in 2025 is considered relatively low, as operational improvements and enhanced market competitiveness have been observed following management adjustments [3] - Final assessments regarding goodwill impairment will depend on formal evaluations from third-party asset assessment firms and audit institutions [3]

Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 2.417 billion yuan, a decrease of 14.55% compared to the same period last year [2] - The non-recurring net profit loss was 49 million yuan, significantly narrowing compared to the previous year [2] - The overall gross margin improved from approximately 26% in 2024 to nearly 30% in the first half of 2025, indicating enhanced operational and contract quality [4] Group 2: Business Strategy and Operations - The company is focusing on improving operational quality, with efforts including increased international business expansion, which saw nearly 40% growth in overseas revenue in the first half of 2025 [2] - Domestic order quality is improving, with new order gross margins gradually returning to normal levels despite intense competition in the domestic market [2] - The company is actively pursuing cost reduction and efficiency improvements across management, R&D, procurement, and manufacturing [2] Group 3: International Business Development - The company’s international business has seen significant changes, with major pharmaceutical companies beginning supplier audits, leading to breakthroughs in cooperation [3] - In the first half of 2025, the company experienced strong growth in the Middle East and Southeast Asia, with hopes of increasing the proportion of international business in the coming years [2][3] - Romaco Group, a subsidiary, is performing well with steady improvements, and currently has no plans for further overseas capacity expansion [3] Group 4: Market Conditions and Competition - The domestic market remains competitive, with price sensitivity; however, the price competition has improved compared to last year, suggesting a bottoming out of pricing pressures [3] - The company plans to selectively abandon low-margin orders to enhance operational quality while maintaining scale [3]